PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused
Contract Development & Manufacturing Organization (CDMO) for peptide- and
oligonucleotide-based active pharmaceutical ingredients. By supporting its customers
mainly in pharma and biotech, it contributes to the health of millions of patients across
the world. PolyPeptide offers products and services from pre-clinical through to
commercial stages, including generics. Its active custom projects pipeline reflects the
opportunities from novel drug therapies in development to fight both widespread and
rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six
cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide Group AG’s shares
(SIX: PPGN) are listed on SIX Swiss Exchange.
Our mission is to help our customers develop products, secure regulatory approvals, and successfully launch and commercialize their products in the market.
Our goal is to provide leading capabilities for the development and manufacturing of peptide and oligonucleotide based APIs (active pharmaceutical ingredients).
Our customers are our focus. We strive to be the preferred partner by consistently setting, managing, and meeting their
expectations.